New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:41 EDTINCYIncyte says FDA accepts sNDA for Jafaki
Incyte Corporation announced that the U.S. FDA has accepted for filing the supplemental New Drug Application for ruxolitinib as a potential treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. The sNDA includes results from the RESPONSE Phase III trial, which were recently presented at the 2014 American Society of Clinical Oncology annual meeting. RESPONSE was conducted under a Special Protocol Assessment from the FDA. The Prescription Drug User Fee Act date for the sNDA for ruxolitinib is set for December 5, 2014.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
07:11 EDTINCYImmunoVaccine announces collaboration with Incyte
Subscribe for More Information
June 23, 2015
07:25 EDTINCYPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 19, 2015
07:05 EDTINCYIncyte says EVP, Chief Commercial Officer Jim Daly to leave at end of June
Subscribe for More Information
June 18, 2015
11:53 EDTINCYIncyte management to meet with SunTrust
Subscribe for More Information
06:55 EDTINCYIncyte management to meet with JMP Securities
Meetings to be held in New York on June 18 and in Boston on June 19 hosted by JMP Securities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use